Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Biol Clin (Paris). 2012 Jul-Aug;70(4):405-11.

[Hereditary hemochromatosis HFE: regulatory and economic aspects of diagnosis and medical management].

[Article in French]

Author information

  • 1Laboratoire de biochimie, CHU de Rennes. martine.ropert@chu-rennes.fr

Abstract

HFE hereditary hemochromatosis is a chronic illness (ALD n(o) 17 - Maladies métaboliques et héréditaires) which is the first genetic disease in France (60% of all genetic diseases). The list of medical acts and the services supported by the French national health insurance fund are fully codified by the French national authority for health (HAS) in order to reduce unnecessary health care spending. The search for the C282Y mutation of the HFE gene to confirm the diagnosis is supported by French national health insurance fund since 2007 (under certain conditions). Treatment by phlebotomy is well established. It should begin in hospital and is generally well tolerated. Since April 2009, the use of the patient's blood (phlebotomy - blood donations) in French blood centers provides an additional contribution to blood transfusion. However, if this genetic disease is well known to the scientific viewpoint (mechanism and toxicity of iron overload, gene…) and therapeutically (bleeding), the diagnosis is always made too late by ignorance of the symptoms.

PMID:
22796612
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Libbey Eurotext
    Loading ...
    Write to the Help Desk